Latest Conference Articles

Program for Angiogenesis 2022 ignites excitement in ophthalmologists

Program for Angiogenesis 2022 ignites excitement in ophthalmologists

January 25th 2022

Angiogenesis

The meeting places a special emphasis on pharmacotherapies in the pipeline for the treatment of neovascular exudative diseases of the eye and how they will affect clinical practice and Medicare.

Ophthalmic bevacizumab effectively treats wet macular degeneration, NORSE TWO concludes

Ophthalmic bevacizumab effectively treats wet macular degeneration, NORSE TWO concludes

January 21st 2022

AAO

Firas Rahhal, MD, discusses Outlook Therapeutics’ Phase 3 pivotal NORSE TWO trial for ONS-5010.

Using the IRIS registry to analyze ancillary testing patterns on a per patient basis

Using the IRIS registry to analyze ancillary testing patterns on a per patient basis

January 6th 2022

AAO

Ted Leng, MD, discusses his presentation, “Variations in Vitreoretinal Physician Utilization of Ancillary Testing: An IRIS Registry Analysis” during Retina Specialty Day at AAO 2021.

AAO 2021 reinvigorates ophthalmologists for 2022

AAO 2021 reinvigorates ophthalmologists for 2022

December 23rd 2021

AAO

Dr. McDonnell highlights inspiring moments from the 2021 annual meeting of the American Academy of Ophthalmology, along with a look ahead to next year’s conference in Chicago.

Reflecting on key takeaways from AAO 2021 with Peter J. McDonnell, MD

Reflecting on key takeaways from AAO 2021 with Peter J. McDonnell, MD

December 16th 2021

AAO

Peter J. McDonnell, MD, shares some of many highlights from this year’s annual meeting of the American Academy of Ophthalmology in New Orleans.

Brolucizumab shows evidence of retinal drying in wet AMD

Brolucizumab shows evidence of retinal drying in wet AMD

December 15th 2021

AAO

Jill Hopkins, MD, discusses results from phase 3a of the Merlin trial for brolucizumab as a treatment for wet AMD and provides updates on KESTREL and KITE trials for the treatment of diabetic macular edema.

ARMOR study: data sheds light on antibiotic resistance in ophthalmology

ARMOR study: data sheds light on antibiotic resistance in ophthalmology

December 8th 2021

AAO

At the 2021 American Academy of Ophthalmology annual meeting, Penny Asbell, MD, FACS, MBA, discussed data from the ARMOR study and its effects on treating ophthalmic infections, such as endophthalmitis.

New sustained-release anti-VEGF formula proves safe and effective in phase 1 trials

New sustained-release anti-VEGF formula proves safe and effective in phase 1 trials

November 26th 2021

AAO

Jay Duker, MD, discusses EYP-1901, EyePoint Pharmaceuticals’ sustained-release anti-VEGF drug for the treatment of wet AMD.

Results from phase 2b study of AR-15512 for the treatment of dry eye

Results from phase 2b study of AR-15512 for the treatment of dry eye

November 22nd 2021

AAO

At AAO 2021, Aerie Pharmaceuticals presented the results of their phase 2b clinical trial of AR-15512, a TRPM8 antagonist, for the treatment of dry eye.

New quality measures dashboard from Verana Health unveiled at AAO

New quality measures dashboard from Verana Health unveiled at AAO

November 19th 2021

AAO

Verana Health showcases the VeraQ quality measures dashboard for the IRIS registry report at AAO 2021.